24 February 2021

NovellusDx Establishes Fore Biotherapeutics U.S. as its Operating Company in the United States & Appoints Dieter Weinand as Chairman of the Board & Usama Malik as Chief Executive Officer and Director of the Board

10 September 2020

Gain Therapeutics Announces Research Collaboration with Sumitomo Dainippon Pharma Co., Ltd to Advance Gain’s Lysosomal Enzyme Allosteric Regulator Program

21 July 2020

Gain Therapeutics, Inc. Announces Close of $10 Million Series B Financing

14 July 2020

3B Future Health Fund Announces New Investment in iOnctura

8 June 2020

QuantuMDx attains CE-IVD marking for SARS-CoV-2 Test

31 January 2020

Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award

30 January 2020

The GreenBone bone substitute achieves CE certification

15 July 2019

Helsinn Investment Fund Announces First Exit

19 March 2019

Winners of the Second Annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced

19 February 2019

Helsinn Investment Fund Invests €1 Million in Gain Therapeutics

23 January 2019

QuantuMDx & St George’s begin field study: cervical cancer screening test

30 April 2018

NovellusDx Announces It Has Completed an Equity Financing of $6 Million

28 March 2018

Winners of the Inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology Announced

14 March 2018

On Target Laboratories Raises Additional Capital from H.I.G. BioHealth Partners, Elevate Ventures and Helsinn

30 January 2018

Helsinn and the Scientific Centre of Monaco Sign Collaboration Agreement

5 September 2017

AMAL Therapeutics Raises €8 Million (CHF 8.8 Million) in First Closing of Series B Financing Round

16 June 2017

Helsinn Investment Fund Leads the Financial Round in GreenBone

8 May 2017

Helsinn Investment Fund Invests in Aadi Bioscience

10 October 2016

Helsinn Group Introduces Helsinn Investment Fund

10 October 2016

Helsinn Investment Fund Invests £2.0 Million in QuantuMDx

10 October 2016

Helsinn Investment Fund to Invest $3.5 Million in OncoResponse

8 August 2016

Helsinn Group and MEI Pharma Enter Strategic Agreement for the Development and Commercialisation of Pracinostat for the Treatment of Acute Myeloid Leukaemia and Other Haematologic Diseases

Get in Touch

For further information, please contact us using the form below.
Someone from the team will be in contact in due course.

Thank you for your form submission, we will get in contact with you shortly.

Copy link
Powered by Social Snap